ORYZON to Present Updated Positive Clinical Data for Iadademstat in Hematological Malignancies at ASH 2026

MADRID and CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a global leader in epigenetics, today announced updated positive clinical data from early-stage clinical trials of its selective LSD1 inhibitor iadademstat in acute myeloid leukemia and in myeloproliferative neoplasms. The findings will be presented in poster sessions at the American Society of Hematology (ASH) 68th Annual Meeting, taking place December 12-15, 2026 in New Orleans, Louisiana.